SCHEMBL3628566

SCHEMBL3628566

Cc1nn(COC(C)[Si](C)(C)C)c2ccc(B(O)OC(C)(C)C(C)(C)O)cc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562422 0.73 ADORA2A (0.36)
SCHEMBL8887683 0.69 ESR1 (0.39)
SCHEMBL8889173 0.68 ADORA2A (0.41)
SCHEMBL8048 0.67 MAP2K4 (0.33)
SCHEMBL16819113 0.64 KDM4E (0.44)
SCHEMBL16241024 0.64 MAPT (0.47)
SCHEMBL15940278 0.64 KIF11 (0.33)
SCHEMBL3455207 0.64
SCHEMBL2693281 0.62 PRKCI (0.41)
SCHEMBL8533 0.62 ADORA2A (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700601-B2 Substituted indazoles of formula 1.0 that are kinase inhibitors SCHERING CORPORATION (US) 2010-04-20 US disclosed
EP-2001870-A2 KINASE INHIBITORS SCHERING CORPORATION (US) 2008-12-17 EP disclosed
US-20080021019-A1 immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds SCHERING CORPORATION 2008-01-24 US disclosed
WO-2007126964-A2 KINASE INHIBITORS SCHERING CORPORATION (US) 2007-11-08 WO disclosed